Literature DB >> 3542363

Biochemistry and biology of anaphylatoxins.

T E Hugli.   

Abstract

The molecular architecture of anaphylatoxins has been explored on several levels. Primary, secondary and tertiary structural parameters that dictate function of the C3a, C4a and C5a molecules are being elucidated with the aid of comparative sequence analyses, physical measurements and organic syntheses. Although C3a, C4a and C5a are biologically distinct mediators, as defined by their unique receptor systems, a common genetic origin is apparent from conserved features in their primary structures. Evidence is now available which suggests that similarities in the folding pattern of the anaphylatoxins may dictate a concensus conformation for each factor. We have learned from synthetic peptide studies that the binding (e.g. effector) site in anaphylatoxin molecules exists as a linear sequence contained in the C-terminal portion of the polypeptide. What is also evident is that a preferred conformation is defined for the binding site requiring a proper side chain orientation for optimal bioactivity. It is proposed that folding of the native structure stabilizes this conformation at the binding site. The binding site in C3a contains the essential residues LGLAR folded in an irregular or pseudo-beta-turn and stabilized by an adjacent alpha-helical segment. It is proposed that the alpha-helical segment influences orientation of the side chain residues in the 'binding site'. A similar model is evolving for C5a based on synthetic C5a peptides that express both spasmogenic and chemotactic activities. This helix turn model promises to be representative of an essential structural feature that determines anaphylatoxin activity. We believe that these models contribute significantly to our understanding of the molecular relationships between structure and function for these humoral mediators of inflammation.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3542363     DOI: 10.1159/000467889

Source DB:  PubMed          Journal:  Complement        ISSN: 0253-5076


  32 in total

Review 1.  Evolution of complement as an effector system in innate and adaptive immunity.

Authors:  J Oriol Sunyer; Hani Boshra; Gema Lorenzo; David Parra; Bruce Freedman; Nina Bosch
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

2.  Bacterial motility is a colonization factor in experimental urinary tract infection.

Authors:  A Siitonen; M Nurminen
Journal:  Infect Immun       Date:  1992-09       Impact factor: 3.441

Review 3.  Complementopathies.

Authors:  Andrea C Baines; Robert A Brodsky
Journal:  Blood Rev       Date:  2017-02-06       Impact factor: 8.250

Review 4.  Pathogenesis and pathophysiology of pneumococcal meningitis.

Authors:  Barry B Mook-Kanamori; Madelijn Geldhoff; Tom van der Poll; Diederik van de Beek
Journal:  Clin Microbiol Rev       Date:  2011-07       Impact factor: 26.132

5.  Generation of complement C3 and expression of cell membrane complement inhibitory proteins by human bronchial epithelium cell line.

Authors:  S Varsano; M Kaminsky; M Kaiser; L Rashkovsky
Journal:  Thorax       Date:  2000-05       Impact factor: 9.139

6.  Complement activation and the prognostic value of C3a in patients at risk of adult respiratory distress syndrome.

Authors:  G Zilow; J A Sturm; U Rother; M Kirschfink
Journal:  Clin Exp Immunol       Date:  1990-02       Impact factor: 4.330

Review 7.  The complement system: history, pathways, cascade and inhibitors.

Authors:  P N Nesargikar; B Spiller; R Chavez
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2012-06-13

Review 8.  Biological properties of human C5a: selected in vitro and in vivo studies.

Authors:  K B Yancey
Journal:  Clin Exp Immunol       Date:  1988-02       Impact factor: 4.330

9.  Design and biological activity of a new generation of synthetic C3a analogues by combination of peptidic and non-peptidic elements.

Authors:  R Gerardy-Schahn; D Ambrosius; M Casaretto; J Grötzinger; D Saunders; A Wollmer; D Brandenburg; D Bitter-Suermann
Journal:  Biochem J       Date:  1988-10-01       Impact factor: 3.857

10.  Fluvastatin treatment inhibits leucocyte adhesion and extravasation in models of complement-mediated acute inflammation.

Authors:  F Fischetti; R Carretta; G Borotto; P Durigutto; R Bulla; P L Meroni; F Tedesco
Journal:  Clin Exp Immunol       Date:  2004-02       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.